Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurooncol ; 128(3): 463-71, 2016 07.
Article in English | MEDLINE | ID: mdl-27147083

ABSTRACT

Systemic administration of etoposide is effective in treating metastatic, recurrent or refractory brain tumors, but penetration into the cerebrospinal fluid is extremely poor. This study was designed to determine the safety and toxicity profile of intraventricular etoposide administration and was affiliated with the prospective, multicenter, nonblinded, nonrandomized, multi-armed HIT-REZ-97 trial. The study enrolled 68 patients, aged 1.1-34.6 (median age 11 years). Adverse events that could possibly be related to intraventricular etoposide therapy were documented and analyzed. Intraventricular etoposide was simultaneously administered with either oral or intravenous chemotherapy in 426 courses according to three major schedules varying in dosing (0.25-1 mg), frequency of administration (bolus injection, every 12 or 24 h), course duration (5-10 days) and length of interval between courses (2-5 weeks). Potential treatment-related adverse effects included transient headache, seizures, infection of the reservoir, nausea and neuropsychological symptoms. Hematological side effects were not observed. One patient, with history of multiple prior therapies, who received long-term intraventricular and oral etoposide treatment developed acute myeloid leukemia as a secondary malignancy. Overall intraventricular etoposide is well tolerated. The results of this study have warranted a phase II trial to determine the effectiveness of this regimen in disease stages with very limited therapeutic options.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Brain Neoplasms/drug therapy , Etoposide/administration & dosage , Adolescent , Adult , Antineoplastic Agents, Phytogenic/adverse effects , Cerebral Ventricles , Child , Child, Preschool , Drug Therapy, Combination , Etoposide/adverse effects , Female , Follow-Up Studies , Humans , Infant , Male , Treatment Outcome , Young Adult
2.
Int J Radiat Oncol Biol Phys ; 88(5): 1019-24, 2014 Apr 01.
Article in English | MEDLINE | ID: mdl-24661654

ABSTRACT

PURPOSE: To evaluate the efficacy of craniospinal irradiation (CSI) in the management of recurrent infant medulloblastoma after surgery and chemotherapy alone. METHODS AND MATERIALS: Seventeen pediatric medulloblastoma patients registered in the HIT-REZ 1997 and 2005 studies underwent CSI as salvage treatment at first recurrence. All patients had achieved complete remission after first-line treatment consisting of surgery and chemotherapy. Eleven patients showed metastatic disease at relapse. Five patients underwent surgery prior to radiation therapy, which resulted in complete resection in 1 case. In 1 patient, complete resection of the residual tumor was performed after CSI. Eleven patients received chemotherapy prior, 6 patients during and 8 patients after CSI. All patients received CSI with a median total dose of 35.2 Gy, and all but 1 received a boost to the posterior fossa (median total dose, 55.0 Gy). Metastases were boosted with an individual radiation dose, depending on their location and extent. RESULTS: During a median follow-up time of 6.2 years since recurrence, 11 patients showed progressive disease and died. Median progression-free (overall) survival was 2.9 ± 1.1 (3.8 ± 0.8) years. Progression-free survival (PFS) rates at 1, 3, and 5 years were 88% ± 8%, 46% ± 12%, and 40% ± 12%, respectively. Overall survival (OS) rates at 1, 3, and 5 years were 94% ± 6%, 58% ± 12%, and 39% ± 12%, respectively. For 11 patients with classic medulloblastoma, 3-year (and 5-year) PFS and OS were 62% ± 15% and 72% ± 14% (52% ± 16% and 51% ± 16%), respectively. On univariate analysis, metastatic disease was not associated with poorer progression-free and overall survival. CONCLUSIONS: Our results suggest that salvage treatment of relapsed medulloblastomas consisting of CSI and chemotherapy offers a second chance for cure, even for patients with classic histological findings. Metastatic disease at relapse did not have an impact on survival. However, this may be explained by the small number of patients.


Subject(s)
Brain Neoplasms/radiotherapy , Cranial Irradiation/methods , Medulloblastoma/radiotherapy , Brain Neoplasms/drug therapy , Brain Neoplasms/surgery , Child , Child, Preschool , Cohort Studies , Disease-Free Survival , Female , Follow-Up Studies , Humans , Infant , Male , Medulloblastoma/drug therapy , Medulloblastoma/surgery , Multivariate Analysis , Neoplasm Metastasis , Neoplasm Recurrence, Local , Neoplasm Staging/methods , Proportional Hazards Models , Radiotherapy Dosage , Recurrence , Salvage Therapy/methods , Time Factors , Treatment Outcome
3.
Anticancer Drugs ; 20(9): 794-9, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19617818

ABSTRACT

This retrospective study aimed to evaluate the safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with refractory or recurrent brain tumors. Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4-22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1). Eighteen patients received concomitant systemic radiochemotherapy. A total of 88 intrathecal injections of liposomal cytarabine (dose range, 20-50 mg) were administered with concomitant dexamethasone prophylaxis. The median number of doses per patient was four (range, 1-10). Duration of treatment ranged from (1/2) to 10 months. Eleven patients (57.9%) did not show any side effects, whereas eight patients (42.1%) developed side effects related to either chemical arachnoiditis (n = 4) or neurological progression (n = 2). Less typical treatment-related symptoms (e.g. lethargy, ataxia, and slurred speech) were observed in two patients. Treatment with intrathecal liposomal cytarabine was discontinued twice because of side effects. In conclusion, although intrathecal liposomal cytarabine was generally well tolerated, it should be used cautiously and only with dexamethasone prophylaxis in extensively pretreated patients with recurrent brain tumors. Proof of efficacy requires a prospective single-agent phase II study.


Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Brain Neoplasms/drug therapy , Cytarabine/administration & dosage , Cytarabine/adverse effects , Adolescent , Antimetabolites, Antineoplastic/administration & dosage , Brain Neoplasms/diagnosis , Child , Child, Preschool , Compassionate Use Trials , Delayed-Action Preparations , Drug Resistance, Neoplasm , Female , Humans , Infant , Injections, Spinal , Liposomes/administration & dosage , Male , Retrospective Studies , Salvage Therapy , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...